Back to R2 link
Top Industry News
- PMDA Japan Changes Electronic Study Data Submission Requirements
- Swissmedic Health Risks of Designer Drugs: Further Psychoactive Substances Prohibited
- Significant Progress in Cosmetics Safety: California Greenlights Prohibition of 26 Additional Hazardous Chemicals Associated with Health Risks
- ANVISA Nutritional Labeling: Defined Deadline for Using Old Packaging
- PMDA Medical Safety Measures Related to Pharmaceuticals and Medical Devices
- FDA Submission of Premarket Notifications for Magnetic Resonance Diagnostic Devices
- Recent Letter Update by New International Fragrance Association (IFRA)
- FDA Testing and Labeling Medical Devices for Safety in the Magnetic Resonance (MR) Environment
- PMDA Information Regarding Reception of Clinical Trial Plan Notifications, etc.
- New Streamlined Notification Scheme for Lowest-risk Clinical Trials Marks Start of MHRA Overhaul of Regulation
- PMDA Information Regarding Determination of Side Effect Relief Benefits
- MHRA Clinical Trials for Medicines: Apply for Authorisation in the UK
- ICMRA (International Coalition of Medicines Regulatory Authorities)
- FDA Quality Considerations for Topical Ophthalmic Drug Products
- California Leads the Way as the First State to Prohibit Four Harmful Chemicals in Food
- FDA's CDRH Proposed Guidances for Fiscal Year 2024(FY2024)
- European Union | Stearyl Tartrate (E 483) as a Food Additive
- MHRA Full Pack Dispensing of Valproate-Containing Medicines